Literature DB >> 8942150

Reactions in leprosy: an epidemiological study of 386 patients in west Nepal.

W H Van Brakel1, I B Khawas, S B Lucas.   

Abstract

This paper presents epidemiological data on reversal reaction (RR) and erythema nodosum leprosum reaction (ENL) from a retrospective study of 386 leprosy patients newly registered at Green Pastures Hospital, Pokhara, West Nepal. The average follow-up time was 21 months. The prevalence of RR at first examination was 28% (23-32), and the prevalence of ENL reaction was 5.7% (2.3-9.2). The overall incidence rates among the 335 patients that were available for follow-up were 8.7 (6.5-12)/100 person years at risk (PYAR) for RR and 3.2 (1.5-6.7)/100 PYAR for ENL. Relapse of RR was common (1.4/patient). In all, 52% of RR were complicated by new nerve function impairment, against 59% of ENL reactions. The finding of other investigators that most RRs occur during the first year of treatment was confirmed by this study. The most significant risk factor for RR was extent of clinical disease measured by a count of body areas with clinical signs of leprosy. The risk of developing a RR for patients with 'extensive disease' (3 or more out of 9 body areas involved) was 10 times that of patients with limited disease (Rate Ratio 10 (1.3-76), p = 0.026). The study indicated that the following categories of patients in Nepal are at high or increased risk of developing a RR: 1, borderline patients during their first year of MDT; and 2, patients with more extensive clinical disease as described above.

Entities:  

Mesh:

Year:  1994        PMID: 8942150     DOI: 10.5935/0305-7518.19940019

Source DB:  PubMed          Journal:  Lepr Rev        ISSN: 0305-7518            Impact factor:   0.537


  13 in total

1.  Reactions following completion of 1 and 2 year multidrug therapy (MDT).

Authors:  Ma Victoria F Balagon; Robert H Gelber; Rodolfo M Abalos; Roland V Cellona
Journal:  Am J Trop Med Hyg       Date:  2010-09       Impact factor: 2.345

2.  Circulating levels of insulin-like growth factor-I (IGF-I) correlate with disease status in leprosy.

Authors:  Luciana Silva Rodrigues; Mariana Andrea Hacker; Ximena Illarramendi; Maria Fernanda Miguens Castelar Pinheiro; José Augusto da Costa Nery; Euzenir Nunes Sarno; Maria Cristina Vidal Pessolani
Journal:  BMC Infect Dis       Date:  2011-12-13       Impact factor: 3.090

Review 3.  Understanding the type 1 reactional state for early diagnosis and treatment: a way to avoid disability in leprosy.

Authors:  José Augusto da Costa Nery; Fred Bernardes Filho; Juliana Quintanilha; Alice Miranda Machado; Soraya de Souza Chantre Oliveira; Anna Maria Sales
Journal:  An Bras Dermatol       Date:  2013 Sep-Oct       Impact factor: 1.896

4.  A genome wide association study identifies a lncRna as risk factor for pathological inflammatory responses in leprosy.

Authors:  Vinicius M Fava; Jeremy Manry; Aurélie Cobat; Marianna Orlova; Nguyen Van Thuc; Milton O Moraes; Carolinne Sales-Marques; Mariane M A Stefani; Ana Carla P Latini; Andrea F Belone; Vu Hong Thai; Laurent Abel; Alexandre Alcaïs; Erwin Schurr
Journal:  PLoS Genet       Date:  2017-02-21       Impact factor: 5.917

5.  Leprosy--evolution of the path to eradication.

Authors:  Sunil Dogra; Tarun Narang; Bhushan Kumar
Journal:  Indian J Med Res       Date:  2013-01       Impact factor: 2.375

Review 6.  A systematic review on the epidemiological data of erythema nodosum leprosum, a type 2 leprosy reaction.

Authors:  Carlijn G N Voorend; Erik B Post
Journal:  PLoS Negl Trop Dis       Date:  2013-10-03

7.  Intraneural injection of corticosteroids to treat nerve damage in leprosy: a case report and review of literature.

Authors:  Sherine G Nashed; Tarek A Rageh; Emad S Attallah-Wasif; Alaa A Abd-Elsayed
Journal:  J Med Case Rep       Date:  2008-12-09

8.  Gene set signature of reversal reaction type I in leprosy patients.

Authors:  Marianna Orlova; Aurélie Cobat; Nguyen Thu Huong; Nguyen Ngoc Ba; Nguyen Van Thuc; John Spencer; Yohann Nédélec; Luis Barreiro; Vu Hong Thai; Laurent Abel; Alexandre Alcaïs; Erwin Schurr
Journal:  PLoS Genet       Date:  2013-07-11       Impact factor: 5.917

9.  Is CXCL10/CXCR3 axis overexpression a better indicator of leprosy type 1 reaction than inducible nitric oxide synthase?

Authors:  Ira Sharma; Avninder Singh; Ashwani K Mishra; L C Singh; V Ramesh; Sunita Saxena
Journal:  Indian J Med Res       Date:  2015-12       Impact factor: 2.375

10.  Will cases of leprosy reaction increase with COVID-19 infection?

Authors:  Douglas Eulálio Antunes; Isabela Maria Bernardes Goulart; Luiz Ricardo Goulart
Journal:  PLoS Negl Trop Dis       Date:  2020-07-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.